Litman Gregory Wealth Management LLC Cuts Position in Edwards Lifesciences Corporation $EW

Key Points

• Litman Gregory Wealth Management LLC reduced its stake in Edwards Lifesciences by 10.4%, owning 144,792 shares valued at $11.32 million after selling 16,844 shares in the second quarter.
• Recent performance reports revealed Edwards Lifesciences beat earnings estimates with $0.67 earnings per share, exceeding expectations by $0.05, and reported quarterly revenue of $1.53 billion.
• Multiple firms have upgraded their ratings for Edwards Lifesciences, with price targets raised, including Wells Fargo increasing its target from $84.00 to $88.00, indicating strong investor confidence in the company's future.

Litman Gregory Wealth Management LLC decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 144,792 shares of the medical research company's stock after selling 16,844 shares during the quarter. Litman Gregory Wealth Management LLC's holdings in Edwards Lifesciences were worth $11,324,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Pacific Capital Partners Ltd purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $1,760,000. Czech National Bank lifted its stake in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock valued at $11,214,000 after purchasing an additional 7,917 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the period. Finally, Dynamic Advisor Solutions LLC boosted its holdings in shares of Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $77.03 on Monday. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $78.50 and a two-hundred day simple moving average of $76.01. The stock has a market capitalization of $45.22 billion, a price-to-earnings ratio of 11.08, a P/E/G ratio of 3.71 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The firm's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EW. Wells Fargo & Company increased their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Finally, Barclays raised their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus price target of $86.61.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.